Navigation Links
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Date:12/13/2011

RICHMOND, Calif., Dec. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct a disease gene in an adult mouse model of hemophilia B using systemic delivery of zinc finger nucleases (ZFNs) at the 53nd Annual Meeting of the American Society of Hematology (ASH).

"We have demonstrated functional correction of a human gene for the clotting factor, Factor IX, with a single, systemic administration of ZFNs in an animal model of disease," said Geoff Nichol, M.B, Ch.B., Sangamo's executive vice president of research and development.  "Our approach enables permanent correction of the genetic defect responsible for hemophilia B.  This circumvents the problems of traditional gene-addition approaches that uncouple the gene from its normal regulatory mechanism and which may result in gene silencing and random gene insertion and potentially lead to malignancy or other unintended consequences."

Abst. No.668 - Robust Factor IX Expression Following ZFN-mediated Genome Editing in an Adult Mouse Model of Hemophilia B (Oral Session: 801)

In this study, scientists demonstrated efficient ZFN-mediated gene correction in an adult mouse model of hemophilia B with a single systemic administration of ZFNs and a donor DNA sequence encoding the corrected human Factor IX gene. Stable levels of protein made from the corrected human gene could be measured in the plasma of the treated animals and resulted in the restoration of normal rates of blood clotting for the period of the study.  This work expands upon earlier studies, published in Nature*, that demonstrated similar results in neonatal mice.  Data described at the ASH meeting demonstrate that growth of liver cells, as is observed in neonates, is not required for efficient
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
3. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
5. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
6. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
7. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
8. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo Announces Pricing of Public Offering of Common Stock
11. Sangamo Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
(Date:7/29/2014)... 2014) Tough, ultralight foam of atom-thick sheets can ... chemical process invented at Rice University. , In ... nanoscale building, with floors and walls that reinforce each ... materials: floors and walls of graphene oxide that self-assemble ... , The researchers say the foam could find use ...
(Date:7/29/2014)... NEW YORK , July 29, 2014  Pomerantz ... Impax Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  ... Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. ... certain of its officers and/or directors have violated Sections ... 1934.  On July 29, 2014, Impax ...
(Date:7/29/2014)... Pa. , July 29, 2014  Discovery ... dedicated to advancing a new standard of respiratory ... results on August 5, 2014 before the open ... The Company will host a live teleconference and ... During the conference call, Discovery Labs, management will ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... Christenson will assume duties as director of the state ... Secretary Cory Nettles announced the hire last ... initiative. , ,Part of the key to our ... in collaborative efforts. We hope to connect the tech ...
... For Ron Reynolds, an early peek at what would turn ... Way came through a hole in the ceiling. , ,As ... late 1970s, Reynolds sawed a hole in the ceiling of ... a specially built spectrometer through the roof of the building, ...
... of molten steel as the representative symbol of a ... the cubicle farm. Instead of coke and iron ore, ... data and information into knowledge and ideas: An invisible ... output is knowledge. Every physical product has a knowledge ...
Cached Biology Technology:Nettles Names Christenson as Director of Bureau of Entrepreneurship 2Journey Leads Astronomer to New Galactic Structure 2Journey Leads Astronomer to New Galactic Structure 3Transforming Information to Knowledge 2
(Date:7/29/2014)... Northern Territories in Canada and have sent smoke drifting ... on. NASA,s Aqua satellite collected this natural-color image ... July 26, 2014. Actively burning areas, detected by MODIS,s ... smoke are drifting northward in this image. Smoke ... Fire has caused power outages in the area and ...
(Date:7/29/2014)... Kent has shown for the first time how the ... could have a major impact on cancer therapy development. ... the mechanism whereby the physical properties of the internal ... are ,fine-tuned, to undertake different functions. , While some ... a framework for the cell, others are more dynamic, ...
(Date:7/29/2014)... ground breaking new book that brings together two of ... raise the profile of insect fossils through stunning photographs ... Penney and James E Jepson, details the incredible preservation ... setting the scene for what these remarkable fossils can ... even the future of our planet. Like the mosquito ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2
... engineered yeast strain can simultaneously consume two types of ... sugars are glucose, a six-carbon sugar that is relatively ... has been much more difficult to utilize in ethanol ... adding to earlier advances, reduces or eliminates several major ...
... 24, 2010) - Three weeks of oral resveratrol or ... microRNA activity close to their pre-event levels in excised ... were attributed to exerting the majority of the gene-switching ... microRNA optimally regulated by Longevinex and two optimally by ...
... New findings from the Monell Center reveal that weight ... formula the infant is consuming. The findings have implications related ... and other diseases later in life. "Events early in ... most significant influences is early growth rate," said study lead ...
Cached Biology News:Team overcomes major obstacles to cellulosic biofuel production 2Team overcomes major obstacles to cellulosic biofuel production 3Team overcomes major obstacles to cellulosic biofuel production 4Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3Not all infant formulas are alike: Differential effects on weight gain 2
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
ASCIZ...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
...
Biology Products: